What happened

Applied Nutrition reported a 43.9% rise in annual pre-tax profit to £41 million as revenue increased 50.9% to £161.6 million. The figures cover the year ended 31 July 2026 and come from unaudited preliminary results published on Monday. The Liverpool-based supplements business kept its expectations for the following financial year unchanged.R1R3S3

The company launched a range aimed at people using GLP-1 weight-loss medication during the year. Chief executive Thomas Ryder says new products are bringing in customers beyond its traditional sports nutrition audience. The group also says its partnership with Coleen Rooney has broadened its appeal.S3

Why it matters

The figures need care because coverage uses different profit measures. City AM describes £40.6 million as pre-tax profit and says profit nearly doubled. The company's results identify £40.6 million as operating profit, up 44.5%, and £41 million as pre-tax profit, up 43.9%. Neither of those measures nearly doubled.R1S4

Profit growth also did not translate into higher free cash flow. The company's measure fell 35.8%, from £16.5 million to £10.6 million. It paid no dividend during the year, compared with £14.7 million a year earlier, and says it does not expect another before its 2028 financial year.R2

Management says it is keeping cash for additional capacity, efficiency improvements and possible acquisitions. It also says its newly acquired US business needed recapitalisation. The company expects further working capital needs from that business and higher whey purchasing costs, tying up more cash in day-to-day operations.R2

The background

Applied Nutrition mainly sells through other businesses, including retailers, grocers, gyms and sports clubs. Its customers range from professional athletes to people seeking to build muscle or lose weight. The Independent reports that its products are sold in more than 80 countries and that it also sells online.S3

The group says sales of Critical Whey increased 142% following a relaunch. That growth has made whey-based products a larger part of its sales. It expects the average cost of whey to be higher this financial year than last year, despite a recent easing in raw material prices, and says customer price increases partly offset the pressure.S3R3

What happens next

The board continues to expect approximately £205 million in revenue and £49 million in adjusted earnings before interest, tax, depreciation and amortisation for 2026-27. It expects that earnings margin to fall slightly, reflecting whey costs and a greater contribution from lower-margin US sales. These are forecasts rather than results already achieved.R3

The company's calendar lists its annual general meeting for 14 January 2027. Its next half-year ends on 31 January, with interim results scheduled for March.R4